|Bid||109.28 x 800|
|Ask||135.95 x 800|
|Day's Range||122.72 - 129.67|
|52 Week Range||77.50 - 181.07|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
REDWOOD CITY, Calif., Jun 22, 2021--Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Guardant360 Response™ test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA (ctDNA) levels to provide oncologists an early indication of a patient’s response to treatment. The Guardant360 TissueNext™ test, the co
REDWOOD CITY, Calif., Jun 19, 2021--Please replace the release dated April 30, 2021, with the following corrected version due to changes in the fifth paragraph.
REDWOOD CITY, Calif., Jun 18, 2021--Please replace the release dated May 19, 2021 with the following corrected version due to a change in the fourth paragraph.